Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
04. Oktober 2023 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
27. September 2023 16:01 ET
|
Gritstone bio
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433M
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13. September 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor Conferences
05. September 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16. August 2023 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio and Genevant Sciences Announce Option and License Agreement
15. August 2023 07:00 ET
|
Gritstone bio
Agreement provides nonexclusive access to Genevant’s leading LNP technology for use with Gritstone bio’s self-amplifying RNA technology in wide array of infectious disease vaccines Multi-year,...
Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
09. August 2023 16:05 ET
|
Gritstone bio
-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC);...
Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
07. August 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17. Juli 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13. Juni 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...